CD79A and nasopharyngeal carcinoma: Currently, the Chinese Ministry of Health recommends using anti-EBV IgA (VCA-IgA and EBNA1-IgA) serological tests for NPC screening in individuals aged 30 to 69 years in NPC endemic areas (5).